Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 14/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.64 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.64 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.64 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.64 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237283 | 0.93 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL13237208 | 0.92 | ITGB3 (0.55) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL2231781 | 0.91 | ITGB3 (0.77) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL2231789 | 0.91 | ITGB3 (0.77) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL13237253 | 0.91 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL13237248 | 0.91 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL2231257 | 0.89 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL13237287 | 0.89 | ITGAV (0.64) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL2231250 | 0.89 | ITGAV (0.57) | ITGAVITGB3ITGB6ITGA5ITGB1 | |
| SCHEMBL327990 | 0.87 | ITGAV (0.51) | ITGAVITGB3ITGB6ITGA5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7763621-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2010-07-27 | — | — | US | disclosed |
| US-7582640-B2 | Vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS (FR) | 2009-09-01 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | GALAPAGOS SAS | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149476-A1 | Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same | ADGRF1, C5AR2, ADGRE5 | ITGAV 206/4885ITGB3 244/4885ITGB6 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.